|
業務類別
|
Biotechnology |
|
業務概覽
|
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335. |
| 公司地址
| 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011 |
| 電話號碼
| +1 425 939-7410 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.immunome.com |
| 員工數量
| 177 |
| Dr. Clay B. Siegall,PhD |
Chief Executive Officer, President and Chairman of the Board |
美元 735.00K |
24/04/2026 |
| Ms. Sandra G. Stoneman |
Chief Legal Officer and General Counsel |
-- |
24/04/2026 |
| Mr. Kinney Horn |
Chief Business Officer |
-- |
24/04/2026 |
| Dr. Jack Higgins, PhD |
Chief Scientific Officer |
-- |
24/04/2026 |
| Mr. Max Rosett |
Chief Financial Officer and Principal Accounting Officer |
美元 472.50K |
24/04/2026 |
| Mr. Robert Lechleider, M.D. |
Chief Medical Officer |
美元 530.30K |
24/04/2026 |
| Mr. Philip Tsai, PhD |
Chief Technical Officer |
-- |
24/04/2026 |
|
|
| Ms. Carol A. Schafer |
Independent Director |
24/04/2026 |
| Dr. Clay B. Siegall,PhD |
Chief Executive Officer, President and Chairman of the Board |
24/04/2026 |
| Mr. Philip Wagenheim |
Independent Director |
24/04/2026 |
| Mr. Jean-Jacques Bienaime |
Independent Director |
24/04/2026 |
| Mr. Isaac Barchas, J.D. |
Lead Independent Director |
24/04/2026 |
| Mr. James P. Boylan, M.B.A. |
Independent Director |
24/04/2026 |
| Dr. Sandra M. Swain, M.D. |
Independent Director |
24/04/2026 |
|
|
|
|
